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The Knops blood group system: a review
 The Knops blood group system finds its roots in the 
group of antibodies that were previously called high-titer, 
low-avidity, or HTLA, antibodies. This term was used to de-
scribe a group of alloantibodies that appeared to have many 
of the same characteristics, including very weak reactions 
at the anti-human globulin (AHG) phase of testing. Howev-
er, as their specificities were more clearly defined, each was 
placed into a blood group system, and Knops became the 
22nd system recognized by the ISBT Committee on Termi-
nology for Red Cell Surface Antigens.1 Since that time, the 
protein bearing the Knops antigens has been identified, the 
gene has been cloned, and all of the known Knops antigens 
have been characterized at the molecular level. This has al-
lowed investigators to more precisely study the role of the 
Knops blood group system in disease.
History
 In 1965, the sera from three unrelated patients (Cope-
land, Stirling, and Wainright) were reported as having an 
antibody with similar specificity.2 The antibody was named 
after the first two antibody producers, Co and St (Cost), 
and given the designation Csa. Ten years later a new anti-
gen, York (Yka) was reported.3 The York serum was initially 
believed to be an example of anti-Csa until the RBCs of the 
donor were found to be Cs(a+). This same study found that 
12 of 1,246 Caucasian donors were both 
Cs(a–) and Yk(a–), suggesting that these 
antigens were at least phenotypically re-
lated. Neither, however, was given blood 
group status, and they became part of the 
HTLA group of antibodies. Even though 
Yka was thought to be associated with Csa 
at this time, it would later be assigned to 
the Knops system.
 Another similar antibody being inves-
tigated in the 1960s was anti-Kna. Anti-Kna 
was described in a transfused Caucasian 
woman who had a saline-reactive anti-K 
plus an unidentified antiglobulin-reactive 
antibody to a high-frequency antigen.4 
The antithetical Knb was later reported in 
the Hall serum, which contained a potent 
anti-Kpb and was being used to screen 
Australian blood donors.5
 The Knops blood group system began to expand when 
Molthan and Moulds6 described a new antigen, McCa, which 
seemed to be related to Kna. They reported that 53 percent 
of McC(a–) samples were also Kn(a–). Interestingly, a ma-
jority of McCa antibody producers were Black whereas most 
of those making anti-Kna were Caucasian, thus suggesting 
that ethnic differences might exist in their respective gene 
frequencies.
 The next pair of alleles, Sla and Vil, was reported in 
separate abstracts with one author using the term McCc for 
Sla and McCd for Vil.7,8 The Sl terminology came from the 
names of the first two antibody producers, i.e., Swain and 
Langley. It was preferred by these authors because they be-
lieved that this antigen was independent from McCoy. After 
identification of the protein bearing the Knops antigens, Sla 
was renamed S11 and Vil became S12.9
 The last high-incidence antigen identified in the Knops 
system was KAM,10 later renamed KCAM by the ISBT Com-
mittee on Terminology for Red Cell Surface Antigens.11 The 
antibody producer was a Caucasian man who exhibited the 
Helgeson phenotype, i.e., serologic Kn null. Like Sla, this 
antigen showed a widely diverse frequency in Blacks vs. 
Caucasians (Table 1). Although KCAM is a high-frequency 





Table 1. Frequency of the Knops antigens in several ethnic groups
Population Kna Knb McCa McCb S11 S12 Yka KCAM Refs.




100% NT 89–92% 49–54% 30–38% 95% NT 20% 10, 14
African 
Americans




98% 2% 93% 42% 70% 86% NT 53% 12
Asian 
Brazilians
100% 0% 100% 0% 100% 0% NT 95% 12
*Marilyn Moulds, personal communication.
Note: The publication by Covas et al.12 incorrectly lists 4870A  
(isoleucine) as being KCAM negative.
NT = not tested.
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Knops Protein
 In 1991, two groups identified complement receptor one 
(CR1) as the protein carrying the Kna, McCa, and Sla blood 
group antigens.15,16 In addition, Moulds et al.15 also located 
Yka to CR1 and suggested that the Helgeson phenotype was 
attributable to low CR1 copy numbers on the erythrocytes 
(E-CR1). Several years later, Petty et al.17 confirmed these 
reports using monoclonal antibody-specific immobiliza-
tion of erythrocyte antigens (MAIEA) analyses and also 
confirmed that Csa was not on CR1. Thus, Csa and Csb have 
remained a collection as defined by ISBT.
 CR1 is a membrane-bound glycoprotein and, with the 
exception of platelets, is found on most human periph-
eral blood cells. Depending on the methods used, erythro-
cytes display approximately 300 to 800 CR1 molecules per 
cell whereas leukocytes display approximately 10,000 to 
30,000 molecules per cell. Because erythrocytes are pres-
ent in the peripheral circulation at concentrations 103-fold 
higher than the peripheral blood mononuclear cells (PB-
MCs), they account for greater than 85 percent of CR1 in 
the blood. E-CR1 binds immune complexes (ICs) that are 
shuttled to the liver or spleen for transfer to and ingestion 
by macrophages, leading to their elimination. IC-free eryth-
rocytes return to the circulation, where they may continue 
participating in IC clearance. We have noted that individu-
als with high CR1 copy numbers may exhibit a weak false-
positive DAT in the gel technique, most likely as a result of 
increased binding of ICs.
Knops Antigen Characteristics
 The Knops antigens can vary greatly in strength (Table 
2), and weakly reactive cells can be falsely phenotyped as 
negative if the cells are stored for some duration or have 
low E-CR1 numbers. Chemicals that can disrupt disulfide 
bonds, i.e., DTT and AET, can destroy Knops, McCoy, 
Swain-Langley, and York antigens because they destroy the 
conformational structure of the short consensus repeats 
(SCRs). There are no examples of these antibodies that are 
enhanced by enzyme treatment of RBCs, and most are still 
reactive (sometimes weaker) with either ficin- or papain-
treated cells.18,19 However, all Knops system antibodies cur-
rently identified are nonreactive with trypsin-treated RBCs. 
It is known that a trypsin cleavage site exists in SCR 28 of 
the CR1 protein. Because the blood group antigens identi-
fied to date have been found in SCR 25, they are lost on 
trypsin treatment of the cells. This fact can be a useful tool 
not only in antibody identification but also for absorption to 
remove other antibodies from a sample.
 Although the variability in antigen strength can be in-
herited, it may also be acquired. Diseases that have high 
levels of ICs being processed, e.g., systemic lupus erythe-
matosus or HIV infection, can cause an increased loss of 
E-CR1, resulting in weakened Knops antigen strength.20 In 
Knops Antibodies
 The Knops antibody characteristics are shown in Table 
3. Two characteristics that were often attributed to Knops 
antibodies were (1) they were not neutralized with plasma, 
saliva, or urine, and (2) they were difficult to adsorb and 
elute. The latter most likely reflects the low density of the 
CR1 protein on the RBC membrane. However, Race and 
Sanger23 reported that adsorption performed with buffy 
coats (WBCs) were able to remove anti-Kna from serum. 
This led to the speculation that anti-Kna and related speci-
ficities were WBC antibodies. The ability of antigen-positive 
WBCs to adsorb Knops antibodies most likely relates to the 
fact that the CR1 copy number on WBCs is in the tens of 
thousands compared with a few hundred on RBCs.
 Although CR1 has not been found in the saliva, low 
levels have been found in both urine24 and plasma.25 These 
are believed to be the result of proteolytic cleavage of CR1 
from leukocytes.26 Serum CR1 is present only in nano-
gram amounts,27 and therefore the levels are insufficient to 
neutralize Knops antibodies using routine serologic tech-
niques. Hence, Moulds and Rowe28 developed an inhibition 
technique using recombinant, soluble CR1 (sCR1). Because 
their source of sCR1 was genetically positive for Kna, McCa, 
Sla, and Yka, it would only inhibit these antibodies and not 
inhibit anti-Knb or McCb. It must be remembered that the 
Knops phenotype of the sCR1 will be dependent on the gene 
chosen for its production. More recently, these investigators 
addition, when RBCs are stored, vesicles are budded from 
the membrane, and these vesicles contain CR1.21 Therefore, 
the longer RBCs are stored, the weaker the Knops antigens 
become. This may explain why In(Lu) RBCs were initially 
reported to have weakened Knops antigens.22
 
Table 2. Characteristics of the Knops antigens
Inherited as Mendelian-dominant traits
High-frequency RBC antigens (except Knb and McCb)
Developed on cord blood cells but may be weaker
Weaker on stored RBCs
Not destroyed by ficin or papain
Destroyed by trypsin treatment
Not found on platelets
Found in low levels in plasma but not in urine or saliva
 
Table 3. Characteristics of Knops system antibodies
Titer is dependent on E-CR1 levels
Can demonstrate variable reactions
Not neutralized by pooled serum or other body fluids
Difficult to adsorb and elute from RBCs
IgG reacting by AHG technique
Do not bind complement
Usually not clinically significant
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have used mutated CR1 constructs to produce peptides ca-
pable of inhibiting anti-McCb and S12 (Vil).29
Clinical Importance
 Because the Knops antibodies are found in the serum 
of multiply transfused individuals, these sera often contain 
additional alloantibodies directed at (for example) K, E, 
and Duffy antigens. Most of the Knops antibodies are not 
considered clinically significant because they do not cause 
overt hemolytic transfusion reactions or hemolytic disease 
of the fetus and newborn. Some examples of Knops sys-
tem antibodies have been studied using in vitro tests such 
as the monocyte monolayer assay (MMA). Arndt and Gar-
ratty30 studied three anti-Kna, three anti-Yka, and five anti-
Kn/McC and found that only one had a macrophage index 
of greater than 20, suggesting increased RBC destruction. 
Other MMA studies of two anti-Kna, two anti-Sla, one anti-
KCAM, and one anti-Yk/Cs all gave indexes of less than 
0, indicating no enhanced RBC destruction (J.J. Moulds, 
unpublished data).
The CR1 Gene
 The CR1 gene resides on chromosome 1 (1q32) and 
comprises 39 exons spread out over approximately 133 
kilobase (kb) pairs of DNA.31 These exons encode SCRs 
of approximately 60 amino acids in the functional CR1 
protein. Seven SCRs are organized into larger units called 
long homologous repeats (LHRs). The most 
common size protein product, CR1-1, is made 
up of four LHRs (A, B, C, D), a transmembrane 
region (TM), and a cytoplasmic tail (CYT), as 
shown in Figure 1. The binding sites for C3b 
and C4b have been localized to SCRs 8-9 and 
15-16 (LHRs B and C) and to SCRs 1-2 (LHR-A), 
respectively.
 The CR1 gene also exhibits two other poly-
morphisms besides the Knops blood group. A 
structural, or size, polymorphism results from 
four different genes encoding four different 
molecular weight proteins: 190 kDa (CR1*3), 220 kDa 
(CR1*1), 250 kDa (CR1*2), and 280 kDa (CR1*4). Owing to 
the looping structure imparted by multiple disulfide bonds, 
the molecular weight shifts downward by approximately 30 
kDa when the proteins are separated on SDS-PAGE using 
nonreducing conditions. It is now known that the molecu-
lar weight polymorphism is independent from the blood 
group polymorphism.
 The third commonly recognized polymorphism is based 
on quantitative differences in E-CR1. A HindIII RFLP is 
detected by two allelic fragments of 7.4 or 6.9 kb on South-
ern blots. Homozygotes for the 7.4-kb fragment are high 
CR1 expressors (H), and homozygotes for the 6.9-kb frag-
ment are low expressors (L) of CR1.32 Alternatively, a PCR-
RFLP can be used that results in a band of 1.8 kb for H or 
1.3 and 0.5 kb for L alleles.33 Although this RFLP correlates 
with RBC expression in Caucasian and Chinese individu-
als,34 there is no relationship between this polymorphism 
and CR1 expression in African Americans35 or West Afri-
cans.36 The exact molecular mechanism regulating CR1 
RBC expression has been elusive but does not appear to be 
part of the promoter or 3′ untranslated portions of the CR1 
gene.37
Molecular Basis of Knops Antigens
 Using CR1 deletion constructs, Moulds et al.29 first lo-
calized the McCoy and S11 (Sla) antigens to LHR-D of CR1. 
By direct DNA sequencing they were then able to identify 
two separate mutations in SCR 25 that correlated with these 
two blood group antigens. The McCa/McCb polymorphism 
is at base pair 4795, where an A encodes proline (McCa) 
and a G encodes aspartic acid (McCb). The S11/S12 muta-
tion is only 11 amino acids away; at base pair 4828, an A 
encodes arginine and a G encodes glycine. Accordingly, the 
ISBT has now assigned these antigens to the Knops system 
with the numbers shown in Table 4.38
 Two other mutations have been identified in SCR 25, 
one of which was found in a Caucasian and is related to 
S11. KMW was initially believed to have produced anti-Sla. 
However, after gene sequencing it was found that she was 
not only homozygous for S11 but was homozygous for an-
other SNP at position 4855 that substituted threonine for 
serine at amino acid 1610. After extensive molecular stud-
ies, Moulds et al.39 proposed a model in which S13 was 
Table 4. Molecular basis of the Knops antigens
ISBT 
number Antigen Nucleotide Nucleotide† Amino acid
KN1 Kna 4708G 4681G Va11561
KN2 Knb 4708A 4681A Met1561
KN3 McCa 4795A 4768A Lys1590
KN4 S11 4828A 4801A Arg1601
KN5 Yka Unknown Unknown Unknown
KN6 McCb 4795G 4768G Glu1590
KN7 S12 4828G 4801G Gly1601
KN8 S13 (provisional) 4828A, 4855T* 4801A, 4828T* Arg1601, Ser1610
KN9 KCAM 4870A 4843A Ile1615
*Note: The publication by Moulds et al.39 incorrectly lists the 4855 mutation as 
A>G. The correct substitution is T>A.
†Nucleotide number when nucleotides are counted beginning with the A of the 
AUG start codon
LHR-A LHR-B LHR-C LHR-D TM CYT
●●●●●●●●●●●●●●●●●●●●●●●●●●●● ╫□
SCR 1–7 SCR 8–14 SCR 15–21 SCR 22–27
Fig. 1. Schematic of the CR1-1 protein bearing the 
Knops antigens in SCR 25.
IMMUNOHEMATOLOGY, Volume 26, Number 1, 2010 5
a conformational epitope needing S11 (1601R) and S14 
(1610S) to react. S14 and the antithetical antigen S15 are 
proposed epitopes awaiting the identification of the appro-
priate antibodies before they can be officially recognized. 
However, the related SNPs can be identified molecularly. 
Limited population studies of Caucasians, Blacks, and 
Asians predict that S14 may be a high-frequency antigen in 
all populations and that S15 predominantly occurs in Cau-
casians.12,39
 The final antigen assigned to the Knops system is KCAM 
(initially reported as KAM). Interestingly, the SNP produc-
ing KCAM was already known but had not been associated 
with a blood group specificity until a McCoy-like antibody 
was found in a Caucasian blood donor. On DNA sequenc-
ing, it was discovered that he was homozygous for an SNP 
at bp 4870 that substituted valine for isoleucine.10 Hence, 
it was assigned the number KN9, and the antigen was re-
named KCAM (KC for the city where the donor was found 
and AM for the donor’s initials).
Disease Associations
 In 1997, Rowe et al.40 identified CR1 as a ligand for 
the rosetting of Plasmodium falciparum–infected RBCs 
with uninfected cells. The ability of erythrocytes infected 
with P. falciparum to form rosettes is a property shown by 
only some parasite isolates, but is of importance because 
it has been associated with severe malaria.41 These authors 
showed that CR1 on uninfected erythrocytes was required 
for the formation of rosettes by demonstrating that CR1-
deficient erythrocytes (Helgeson phenotype) had reduced 
rosetting and soluble recombinant CR1 could inhibit ro-
setting. RBCs having the Sl:–1 phenotype showed reduced 
binding to the parasite rosetting ligand PfEMP1.14 Thus, the 
authors hypothesized that this polymorphism may have 
been selected for in malaria-endemic regions by provid-
ing protection against severe malaria. The hypothesis was 
then tested by studies of Africans in Mali and Kenya, where 
it was found that the combined Knops haplotype Kn(a+)/
McC(a–)/Sl:–1 appeared to be protective.
 CR1, as well as other complement receptors, has been 
identified as a receptor facilitating cell entry for a variety 
of pathogenic organisms. Pathogens using CR1 include 
Leishmania major (monocyte-macrophage),42 Legion-
ella pneumophila (monocyte-macrophage),43 Leishmania 
panamensis,44 and Mycobacterium tuberculosis (mono-
cyte-macrophage).45 In an AABB abstract, Noumsi et al.46 
reported that individuals heterozygous for McCa and McCb 
were less likely to be infected by M. tuberculosis (odds ra-
tio, 0.42; 95% confidence interval, 0.22 to 0.81; P = 0.007). 
These results suggested that McCb may have evolved among 
African populations in the context of M. tuberculosis pres-
sure, and conferred a survival advantage in its heterozygous 
form.
Conclusions
 The molecular identification of the Knops blood group 
polymorphisms holds the promise for a better means of typ-
ing for these antigens, the only exception to this being the 
yet unidentified Yka. Because of the inherited or acquired 
changes in RBC expression of CR1, i.e., Knops antigens, 
genotyping may become the method of choice for identify-
ing these antigens, as it is for those of the Dombrock sys-
tem. It is interesting to note that all of the known Knops 
polymorphisms are in SCR 25 of the CR1 protein. However, 
additional SNPs have been found in the CR1 gene, which 
suggests that the identification of new Knops blood group 
antigens is not yet at an end and will surely provide a chal-
lenge to serologists in the future.
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